Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
INCHI
InChI=1S/C2H5NO/c1-2(3)4/h1H3,(H2,3,4)
FORMULA
C2H5NO
Common name
acetamide
IUPAC name
acetamide
Molecular weight
59.067
clogP
-0.723
clogS
0.321
Frequency
0.0460
HBond Acceptor
1
HBond Donor
2
Total PolarSurface Area
43.09
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01378 | Acetylcysteine |
|
Antiviral Agents; Free Radical Scavengers; Antidotes; Expectorants; Mucolytics; Cough and Cold Preparations; Respiratory System; Ophthalmologicals; Sensory Organs; | Acetylcysteine is used mainly as a mucolytic and in the management of paracetamol (acetaminophen) overdose. |
| FDBD01392 | Lacosamide |
|
Anticonvulsants; Nervous System; Antiepileptics; | Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible. |
| FDBD01402 | Alvimopan |
|
Gastrointestinal Agents; Alimentary Tract and Metabolism; Drugs for Constipation; Peripheral Opioid Receptor Antagonists; | Used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Also investigated for use in the treatment of pain (acute or chronic). |
| FDBD01414 | Armodafinil |
|
Central Nervous System Stimulants; Neuroprotective Agents; Nervous System; Psychoanaleptics; Centrally Acting Sympathomimetics; Psychostimulants, Agents Used for Adhd and Nootropics; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP3A4 Inhibitors; Wakefulness-Promoting Agents; | Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders. |
| FDBD01421 | Agomelatine |
|
Antidepressive Agents; Nervous System; Antidepressants; Psychoanaleptics; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; | Agomelatine is indicated for the treatment of major depressive episodes in adults. |
| FDBD01424 | Peramivir |
|
Antiviral Agents; Enzyme Inhibitors; | Investigated for use/treatment in influenza. |
| FDBD01439 | Degarelix |
|
Gonadotropin-releasing hormone antagonist; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; | Degaralix is used for the management of advanced prostate cancer. |
| FDBD01475 | Capsaicin |
|
Anesthetics, Local; Antipruritics; Anesthetics; Sensory System Agents; Musculo-Skeletal System; Nervous System; Topical Products for Joint and Muscular Pain; Capsaicin and Similar Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; | The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain. |
| FDBD01481 | Ganirelix |
|
Hormone Antagonists; Pituitary and Hypothalamic Hormones and Analogues; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Anti-Gonadotropin-Releasing Hormones; Hypothalamic Hormones; | For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. |
| FDBD01486 | Lanreotide |
|
Antineoplastic Agents; Pituitary and Hypothalamic Hormones and Analogues; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Hypothalamic Hormones; Somatostatin and Analogues; | Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2). |
134 ,
14
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1wdn_ligand_1_2.mol2 | 1wdn | 1 | -5.99 | CC(=O)N | 4 |
| 4g4p_ligand_1_2.mol2 | 4g4p | 1 | -5.96 | C(=O)(N)C | 4 |
| 4kqp_ligand_1_2.mol2 | 4kqp | 1 | -5.96 | CC(=O)N | 4 |
| 1jak_ligand_frag_2.mol2 | 1jak | 1 | -5.94 | C(=O)(N)C | 4 |
| 2ntf_ligand_1_9.mol2 | 2ntf | 1 | -5.91 | C(=O)(N)C | 4 |
| 2jiw_ligand_frag_2.mol2 | 2jiw | 1 | -5.89 | NC(=O)C | 4 |
2564 ,
257
